Innovating Works

GIVASA

Activa
TUMOURPRINT: High Throughput Bioprinting of Tumour Models for Drug Development and Oncology Research BICO GROUP AB tramitó un H2020: H2020-EIC-SMEInst-2018-2020 CELLINK will develop and commercialise TumourPrint - a high throughput platform for bioprinting of live tumour models for pharmaceutical dru...
2018-10-29 - 2021-01-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.